Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Patent
1995-02-17
1997-02-25
Bleutge, John C.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
424449, 514342, 604307, A61F 1300, A61F 1302, A61K 970
Patent
active
056057016
ABSTRACT:
The present invention provides a method for treating a condition associated with muscarinic receptor modulation using a 3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[2.2.2]octane transdermal formulation. The invention provides desired transdermal 3-[3-(hexylthio)-1,2,5-thiadiazol-4-yl]-1,2,5,6-tetrahydro-1-methylpyridin e patch formulations.
REFERENCES:
patent: 4855290 (1989-08-01), Fisher et al.
patent: 4908027 (1990-03-01), Enscore et al.
patent: 5041455 (1991-08-01), Sauerberg et al.
patent: 5043345 (1991-08-01), Sauerberg et al.
patent: 5260311 (1993-11-01), Sauerberg et al.
patent: 5264444 (1993-11-01), Sauerberg et al.
patent: 5344656 (1994-09-01), Enscore et al.
patent: 5474783 (1995-12-01), Miranda et al.
Bymaster Franklin P.
Shannon Harlan E.
Shipley Lisa A.
Valia Kirti H.
Bleutge John C.
Boone David E.
Eli Lilly and Company
Harrison Robert H.
Vorndran-Jones MaCharri
LandOfFree
Transdermal formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1972692